A5081469995- Complement system in diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Platelet Disorders and Treatments
- Frailty in Older Adults
- Pharmaceutical Practices and Patient Outcomes
- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Renal Diseases and Glomerulopathies
- Nutrition and Health in Aging
- Blood groups and transfusion
- Diet and metabolism studies
- Chronic Disease Management Strategies
- Nutritional Studies and Diet
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Atrial Fibrillation Management and Outcomes
- Liver Disease Diagnosis and Treatment
- Immune Cell Function and Interaction
- Venous Thromboembolism Diagnosis and Management
- Hip and Femur Fractures
- Diabetes Treatment and Management
- Chronic Myeloid Leukemia Treatments
- Medication Adherence and Compliance
- Folate and B Vitamins Research
- Pharmaceutical studies and practices
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2019-2025
University of Milan
2019-2025
KU Leuven
2023
Takeda (United States)
2023
United States Food and Drug Administration
2023
Azienda Ospedaliera Universitaria Senese
2023
Policlinico S.Orsola-Malpighi
2023
Ospedale San Paolo
2023
IRCCS Ospedale San Raffaele
2023
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2023
Neurological symptoms related to microthrombosis are the hallmark of acute manifestations acquired thrombotic thrombocytopenic purpura (TTP). Despite achievement hematological remission, patients may report persisting neurological impairment that affects their quality life. To assess long-term neuropsychological consequences TTP, we recruited 35 TTP (77% females, median age at onset 41 years, interquartile range: 35-48) regularly followed our out-patient clinic microangiopathies in Milan...
Data on caplacizumab use for thrombotic thrombocytopenic purpura (TTP) in Italy are missing.• Twenty-six Italian patients were treated with an acute immune TTP episode.• Caplacizumab was effective treating the real-world clinical setting.• Two major bleeds leading to drug discontinuation observed.
The severity of the bleeding phenotype in patients with hemophilia A (HA) broadly correlates degree coagulation factor VIII (FVIII) deficiency plasma. However, FVIII level necessary to achieve goal zero joint bleeds remains unclear. This study aimed identify minimum prevent HA. In this retrospective study, congenital mild HA treated on demand, aged ≥16 years, no history inhibitors, followed at Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Milan, were enrolled. We investigated 270...
Lipid metabolism derangement contributes to increased cardiovascular risk in Rheumatoid Arthritis (RA). It is still debated whether and how tocilizumab, an interleukin-6 receptor inhibitor used active RA, impacts risk. We studied the effect of tocilizumab on regulation macrophage cholesterol homeostasis, measuring patient serum ability respectively load (cholesterol loading capacity, CLC) discharge efflux CEC) cells with cholesterol. Patients RA (n = 8) were before after 4 12 weeks...
Prior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes diminished the ability to perform a rigorous assessment. This 5-year retrospective study assessed epidemiology of iTTP determined whether it displays pattern. Patients with both initial relapsed (defined as disintegrin metalloprotease thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada,...
Background: The aim of pharmacotherapy in people at the end life should be symptom control, more than prolonging life. Drugs for disease prevention therefore discouraged, but this is not usual practice. prevalence unnecessary preventive drugs well described, although some studies suggest it common. Methods: This retrospective longitudinal study describes patients receiving and symptomatic drug treatments admission (T 1 ) before death 2 an Italian hospice. All adults admitted to VIDAS hospice...
Factor V Leiden (FVL) and factor II c.∗97G>A (rs1799963) are genetic risk factors for venous thromboembolism. Their contribution to coronary artery disease (CAD) is less clear.
Not available.